MPP and Merck Strikes Licensing Agreement for Molnupiravir
shot by IP News Shots / 8:45 pm on 28 October, 2021
The Medicines Patent Pool (MPP) and Merck & Co., Inc. known as MSD outside the United States and Canada, have signed a voluntary licensing agreement. This is to encourage affordable access to molnupiravir, an oral COVID-19 antiviral medicine treatment. Merck and Ridgeback Biotherapeutics LP will be jointly developing molnupiravir. Under this agreement, as long as COVID-19 stays classified as a Public Health Emergency concern globally by the World Health Organization, Merck, Ridgeback, and Emory University will not receive royalties for sales of molnupiravir.
Industry: Pharmaceuticals | News Category: Deals - Licensing | Type of IP: Patent
Read more at Business Wire